Brought to you by 
Epimmune and IDM SA merge
22 Mar 2005
Executive Summary
Epimmune (genomics and proteomics research for cancer and infectious disease vaccines) and privately held immunotherapeutics developer IDM SA have agreed to an all-stock reverse merger valued at approximately $135mm. The combined company will retain IDM's name and Epimmune's headquarters in San Diego, CA, and will be publicly listed on the Nasdaq under the ticker symbol IDMI.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epimmune and IDM SA merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice